tirzepatide super responder Tell me in the comments if you're a super responder, slow responder or non- responder. Hope this explanation helps. 💧💧💧#obesitymedicine #glp1 #glp1forweightloss #glp1medication #obesitydoctor #doctorsofinstagram More than 1 in 4

The 1 mL syringe (100 units) Some 1 mL syringes have markings every 2 units rather than every 1 unit

Final Verdict: Research Comparison Feature Tirzepatide Retatrutide Receptor Targets GLP-1, GIP GLP-1, GIP, Glucagon Half-Life ~5 Days ~6 Days Max Published Weight Loss ~21% (72w) ~24% (48w) Liver Fat Reduction Moderate/High Extreme Primary Research Focus Glycemic Control Metabolic Reset / REE Future Outlook: Post-2025 Research Landscape As we look toward 2026 and beyond, the data from the Phase 3 TRIUMPH trials will likely solidify retatrutides position in the metabolic research hierarchy

Participants in the phase 2 trial lost an average of 7 kg (15 lbs) after 16 weeks, significantly more than the placebo group

doi: 10.1007/s40620-020-00738-9 119 LeiterLABainSCBhattDLBuseJBMazerCDPratleyREet al

Out-of-pocket options for the branded medication have lowered in cost and can sometimes be less expensive than compounded options, he says